What do systematic reviews say?

Corticosteroids vs no corticosteroid use

• Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 737 participants
  Moderate

Inhaled corticosteroids vs placebo

It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).

• Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes only
  RR 0.51 [0.26, 1]
  4 studies · 74 participants
  Very low

Corticosteroids vs no corticosteroid use

It is very uncertain whether corticosteroids changes disease‐specific mortality ‐ SJS and TEN (time to compared with no corticosteroids (very low certainty).

• Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
  RR 2.55 [0.72, 9.03]
  2 studies · 56 participants
  Very low

Corticosteroids vs no corticosteroid use

The review found no eligible studies for this question.

• Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Corticosteroids vs no corticosteroid use

The review found no eligible studies for this question.

• Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Corticosteroids vs no corticosteroid use

The review found no eligible studies for this question.

• Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Corticosteroids vs no corticosteroid use

The review found no eligible studies for this question.

• Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Corticosteroids vs placebo

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 165 participants
  Very low

Corticosteroids vs placebo

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 165 participants
  Very low

Corticosteroids vs placebo

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 118 participants
  Very low

Corticosteroids vs placebo

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 118 participants
  Very low

Corticosteroids vs modafinil

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  Very low

Corticosteroids vs modafinil

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  Very low

Corticosteroids vs modafinil

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  Very low

Corticosteroids vs modafinil

• Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  Very low

Corticosteroids vs no corticosteroid use

Corticosteroids probably leads to lower incidence of coronary artery abnormalities compared with no corticosteroid use (moderate certainty).

• Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
  OR 0.32 [0.14, 0.75]
  8 studies · 986 participants
  Moderate

Corticosteroids vs no corticosteroid use

• Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1075 participants
  Moderate

Corticosteroids vs no corticosteroid use

• Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 290 participants
  Low

Corticosteroids vs no corticosteroid use

• Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 178 participants
  Moderate

Corticosteroids vs no corticosteroid use

• Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 119 participants
  Moderate